CD99 is a potential diagnostic and immunological biomarker in pan-cancer
Through this comprehensive pan-cancer analysis, we elucidated novel roles for CD99 in various cancer types, providing important insights for clinical treatment strategies and drug development.
Authors
- Zhengxiang Han (ORCID: https://orcid.org/0000-0003-2463-8933)
- Hao Chen (ORCID: https://orcid.org/0000-0003-0018-480X)
- Haizhu Zhang (ORCID: https://orcid.org/0000-0003-3186-0022)
- Juntao Jiang (ORCID: https://orcid.org/0000-0003-4294-9903)
Institutions
- North China University of Science and Technology (CN)
- Wuhan University (CN)
- Beihai People's Hospital (CN)
- Kaifeng University (CN)
- Renmin Hospital of Wuhan University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1007/s12672-025-03419-w
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China